Targeting tumours by adoptive transfer of immune cells
/in Breast Cancer, International Publications /von 2006-05-01 / Clin. Exp. Pharmacol. Physiol. 2006 May-Jun;33(5-6):569-74Short-term dietary administration of celecoxib enhances the efficacy of tumor lysate-pulsed dendritic cell vaccines in treating murine breast cancer
/in Breast Cancer, International Publications /von 2006-05-01 / Int. J. Cancer 2006 May;118(9):2220-31Cancer immunotherapy using dendritic/tumour-fusion vaccine induces elevation of serum anti-nuclear antibody with better clinical responses
/in Breast Cancer, International Publications /von 2006-04-01 / Clin. Exp. Immunol. 2006 Apr;144(1):41-7Randomized trial of hyperthermia and radiation for superficial tumors
/in Breast Cancer, Hyperthermia, International Publications, Malignant Melanoma /von 2005-05-01 / J. Clin. Oncol. 2005 May;23(13):3079-85Phenotypic and functional characterization of clinical grade dendritic cells generated from patients with advanced breast cancer for therapeutic vaccination
/in Breast Cancer, Dendritic Cells, International Publications /von 2005-02-01 / Scand. J. Immunol. 2005 Feb;61(2):147-56Chemo-immunotherapy of breast cancer using vesiculated alpha-tocopheryl succinate in combination with dendritic cell vaccination
/in Breast Cancer, Dendritic Cells, International Publications /von 2005-01-01 / Nutr Cancer 2005;53(2):177-93Immunotherapy and cancer vaccines in the management of breast cancer
/in Breast Cancer, Dendritic Cells, International Publications /von 2005-01-01 / Curr. Pharm. Des. 2005;11(27):3475-83Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice
/in Breast Cancer, Dendritic Cells, International Publications /von 2004-11-01 / Cancer Res. 2004 Nov;64(21):8022-8Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses
/in Breast Cancer, Dendritic Cells, International Publications /von 2004-07-15 / Clin. Cancer Res. 2004 Jul;10(14):4699-708IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de